Core Viewpoint - VEON Ltd. and Cohen Circle Acquisition Corp. I have executed non-redemption agreements totaling approximately USD 52.3 million, securing the minimum cash condition for the proposed business combination with Kyivstar Group, which is expected to be listed on Nasdaq under the ticker symbol "KYIV" [1][2]. Group 1: Business Combination Details - The closing of the business combination is anticipated in the third quarter of 2025, pending shareholder approval and customary closing conditions [2]. - The business combination will mark Kyivstar Group as the first pure-play Ukrainian company to be publicly listed on a U.S. stock exchange [2]. - Cohen Circle's units, Class A ordinary shares, and warrants are listed on Nasdaq under the ticker symbols "CCIRU," "CCIR," and "CCIRW" respectively [2]. Group 2: Kyivstar Group Overview - Kyivstar Group is Ukraine's leading digital operator, serving over 23 million mobile customers and more than 1.1 million home internet fixed line customers as of December 31, 2024 [3]. - The company provides a wide range of services, including 4G, big data, cloud solutions, cybersecurity, and digital TV [3]. - VEON and Kyivstar Group plan to invest USD 1 billion in Ukraine from 2023 to 2027, focusing on infrastructure, technological development, and charitable donations [3]. Group 3: VEON Overview - VEON operates as a digital operator providing converged connectivity and digital services to nearly 160 million customers across six countries [4]. - The company aims to transform lives through technology-driven services that empower individuals and stimulate economic growth [4]. Group 4: Cohen Circle Overview - Cohen Circle Acquisition Corp. I is a special purpose acquisition company formed to effect a merger or similar business combination with technology and/or financial services businesses [5]. - The company’s units, Class A ordinary shares, and warrants are also listed on Nasdaq under the symbols "CCIRU," "CCIR," and "CCIRW" respectively [5].

The offering is led by a $100 million investment from a single new fundamental institutional investor and includes additional participation from a large existing shareholderThe proceeds will be used to establish performance guarantees and bid bonds, as well as meeting requirements in connection with bids for projects, and in relation to previously announced acquisitionsLondon, United Kingdom--(Newsfile Corp. - June 30, 2025) - Gorilla Technology Group Inc. (NASDAQ: GRRR) ("Gorilla" or the "Company"), a glo ...

Key Takeaways DOCS' enterprise tools now drive growth, with AI usage up 5x and 620K+ prescribers engaged. DOCS' Multi-module campaigns and client portals boost revenue visibility and retention to 119%. Shifting to enterprise brings longer sales cycles, but DOCS is retraining teams to support the pivot.Doximity (DOCS) is gradually transforming from a physician-focused social network into a broader healthcare technology platform. This shift is increasingly anchored in enterprise offerings — workflow tools, ...

Group 1 - TD Synnex Corporation (NYSE: SNX) distributes IT hardware and software, including personal computing, cloud, networking, storage, and other tech solutions [1] - The company has strategically shifted its focus to its advanced solutions portfolio, which includes data center solutions and hyper-converged infrastructure-related hardware [1]

Core Viewpoint - The article emphasizes the potential of dividend stocks as a stable income source for investors amid trade negotiations and geopolitical tensions affecting market sentiment [1] Group 1: Verizon Communications - Verizon Communications declared a quarterly dividend of $0.6775 per share, resulting in a dividend yield of 6.3% [3] - Citi analyst Michael Rollins noted Verizon's goal to double its converged wireless subscriptions from 16% to 17% of its customer base over the next three years [4] - Rollins expects Verizon to add more postpaid phone subscriptions in 2025 and sees Q3 results as a potential catalyst for stock performance [6] - The analyst maintains a buy rating on Verizon with a price target of $48, indicating an under-appreciated value in its financial prospects [7] Group 2: Restaurant Brands International - Restaurant Brands International offers a quarterly dividend of $0.62 per share, translating to an annualized dividend of $2.48 and a yield of approximately 3.7% [9] - The company aims for 8% organic adjusted operating income growth on average between 2024 and 2028 [10] - Evercore analyst David Palmer believes QSR can achieve its profit growth targets despite lower sales projections, citing effective cost management [12] - Palmer reiterated a buy rating with a price target of $86, suggesting a valuation multiple closer to competitors [14] Group 3: EOG Resources - EOG Resources announced a $5.6 billion acquisition of Encino Acquisition Partners, which is expected to enhance its free cash flow and shareholder returns [16] - The company increased its dividend by 5% to $1.02 per share, resulting in a dividend yield of 3.1% [17] - RBC Capital analyst Scott Hanold highlighted the strategic value of the Encino acquisition, maintaining a buy rating with a price target of $145 [18] - Following the acquisition, EOG's net debt to book capital is 0.3x, with a focus on returning 100% of free cash flow to shareholders [20]

Company Overview - Gorilla Technology Group Inc. is headquartered in London, U.K. and operates as a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence, and IoT technology [3] - The company offers a diverse range of solutions including Smart City, Network, Video, Security Convergence, and IoT across various sectors such as Government & Public Services, Manufacturing, Telecom, Retail, Transportation & Logistics, Healthcare, and Education, utilizing AI and Deep Learning Technologies [3] Upcoming Financial Results - The company will hold a conference call on June 18th, 2025, at 4:30 p.m. Eastern time to discuss its financial results for the first quarter of fiscal year 2025, which ended on March 31, 2025 [1][2] - Financial results will be released in a press release prior to the call [1] Technological Expertise - Gorilla Technology specializes in enhancing urban operations, security, and resilience through innovative products that leverage AI for intelligent video surveillance, facial recognition, license plate recognition, edge computing, post-event analytics, and advanced cybersecurity technologies [4] - The integration of these AI-driven technologies aims to empower Smart Cities, improving efficiency, safety, and cybersecurity measures, thereby enhancing the quality of life for residents [4]

CORNELIUS, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Ventures, LLC ("AMV"), the entity that recently filed a patent infringement lawsuit against Broadcom Inc. on April 22, 2025, and engaged a patent monetization and funding agreement with Alpha Modus Holdings, Inc. (NASDAQ: AMOD), today announced that it has filed a patent infringement lawsuit against Cisco Systems, Inc. (NASDAQ: CSCO) in the U.S. District Court for the Western District of Texas, Austin Division on June 9, 2025. The case alleges t ...

June 10, 2025 03:49 AM GMT Telefonica Brasil SA | Latin America M Idea Management Meeting Notes VIV highlighted a broad-based strategy to sustain FCF growth that could drive upside to our numbers. Key Takeaways VIV highlighted 5 pillars to boost FCF: 1) ARPU uplift, 2) Churn reduction, 3) Regulatory tailwinds, 4) Leasing cost optimization, and 5) Lower CAPEX intensity. We hosted a webcast with VIV senior management and present our takes below (key charts on the Appendix ). Product initiatives: VIV highlight ...

AtriCure (ATRC) FY Conference Summary Company Overview - **Company**: AtriCure (ATRC) - **Date of Conference**: June 09, 2025 - **Key Speaker**: Angie Weirich, Chief Financial Officer Key Points and Arguments Industry and Market Dynamics - AtriCure operates in the cardiac surgery and electrophysiology markets, focusing on atrial fibrillation (AFib) treatment and pain management solutions [3][4][19] - The company emphasizes the importance of preventative care in cardiac surgery, highlighting the LEAPS clinical trial and BOXNOAF trial as significant initiatives [3][4][22] Product Portfolio and Innovations - AtriCure's product portfolio includes PFA catheters and the AtriClip device, which are critical in the treatment of AFib and appendage management [4][20] - The company launched the AtriClip Flex Mini and Cryosphere Max probes, contributing to a 14% overall growth in the first quarter [39][28] - AtriCure is focused on expanding its appendage management franchise, with a new generation of AtriClip devices that are smaller and less invasive [20][21] Financial Performance and Growth Projections - AtriCure projects a top-line growth of 11% to 13% for the year, with a strong start at 14% [37][39] - The company is committed to improving profitability alongside double-digit revenue growth, despite facing challenges in the minimally invasive business segment [5][12][38] - The international business is growing rapidly but poses a margin headwind, with potential impacts of 10 to 40 points on margin depending on the country [49][50] Competitive Landscape - AtriCure faces competition from other less invasive treatments, particularly in the PFA catheter space, which has led to distractions for electrophysiologists (EPs) [6][13][40] - The CONVERGE clinical trial is positioned as a durable option for long-standing persistent AFib patients, despite initial challenges in adoption post-launch [10][12][14] Strategic Focus and Future Outlook - The company is prioritizing resource allocation towards its appendage management and pain management segments, while maintaining a cautious approach to the CONVERGE product line [24][28] - AtriCure is exploring new markets, including below-the-knee amputations, with the Cryo XT device set to launch later this year [29][30] - The long-term revenue target is set at $1 billion by 2030, with a focus on accelerating growth through clinical trials and market expansion [69][70] Operational Efficiency and Cost Management - AtriCure is focused on leveraging SG&A expenses and improving gross margins through new product launches and operational efficiencies [58][60] - The company has made significant investments in R&D, particularly in the LEAPS clinical trial, which is expected to yield long-term benefits [61][73] Capital Allocation and M&A Strategy - AtriCure is currently focused on organic growth opportunities rather than acquisitions, emphasizing the importance of maintaining profitability [81][82] - The company is cautious about pursuing M&A that could negatively impact its bottom line trajectory [82] Additional Important Insights - The company is seeing an increase in new accounts despite the competitive pressures from PFA technology [17][24] - AtriCure's approach to training and education for healthcare practitioners has evolved, focusing on impactful methods to enhance customer engagement [62][63] - The management remains optimistic about the future, aiming to continue expanding its addressable market and driving revenue growth [84]

Core Insights - Virtual healthcare services, or telehealth, are becoming a standard in the digital healthcare space, with companies like Hims & Hers Health, Inc. (HIMS) and American Well Corporation (AMWL) emerging as key players in medical consultations and digital health solutions [1][2] Stock Performance & Valuation - HIMS has outperformed AMWL over the past three months, with a 35.1% increase compared to AMWL's 22.3% decline. In the past year, HIMS has rallied 183%, while AMWL has seen a decline of 20.3% [3] - HIMS is trading at a forward 12-month price-to-sales (P/S) ratio of 4.6X, above its three-year median of 2.3X. In contrast, AMWL's forward sales multiple is at 0.4X, below its median of 1.3X [4] Growth Potential for Hims & Hers - HIMS is expanding into new conditions treatable via telehealth, focusing on areas like sleep disorders and hypertension, which align with its business model [7] - HIMS has partnered with Novo Nordisk to enhance accessibility to obesity care, launching a six-month Wegovy access plan at $549/month [8] - Over 65% of new subscribers in 2024 benefited from personalized products, aided by the MedMatch AI tool for customized treatment plans [9] Growth Potential for Amwell - Amwell's platform allows clients to utilize their provider networks for virtual care across various modalities, from primary to specialty care [10] - The Converge platform enables care across in-person, virtual, and automated modalities, supporting interoperability with EHRs [11] - Amwell has a nationwide clinical coverage with around 1,000 active behavioral health providers and partnerships with organizations like the Cleveland Clinic [12] Earnings Projections - The Zacks Consensus Estimate for HIMS' 2025 earnings per share suggests a 166.7% improvement from 2024 [13] - The Zacks Consensus Estimate for AMWL's 2025 loss per share implies a 49.7% improvement from 2024 [15] Price Targets - The average price target for HIMS is $43.00, indicating a potential decline of 17.9% from the last close [17] - The average price target for AMWL is $10.00, suggesting a potential increase of 44.7% from the last close [18] Investment Recommendation - HIMS is viewed as a more stable and financially sound investment opportunity, with strong profitability and user engagement, generating substantial free cash flow [21] - AMWL is recognized for its rapid growth and expansion but is considered a lower-ranked investment option compared to HIMS [22]